Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse ...
Recursion Pharmaceuticals (RXRX) is upgraded to Buy, driven by promising REC-4881 data and analyst optimism for FAP market potential. REC-4881's Phase 1b/2 results show a 43% median polyp burden ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback